14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs SRPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas SRPT carries 36.8/100 (SELL) at $15.14 (10.8x Forward P/E, -0.4% operating margin).
Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (42.1/100 HOLD vs. SRPT 36.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. -222.7% operating margin) and revenue trajectory (-4.5% vs. +4505.6% YoY).
Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile SRPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $1.7B market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment23.8% of Rev ($466M)
90D Engineering Disclosures0 Published
Investor FAQ FDMT vs SRPT Key Questions & Quantitative Answers
As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). FDMT carries a Unified Composite Score of 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin), whereas SRPT carries 36.8/100 (SELL) at $15.14 (10.8x Forward P/E, -0.4% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (42.1/100 HOLD vs. SRPT 36.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. -222.7% operating margin) and revenue trajectory (-4.5% vs. +4505.6% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile SRPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with SRPT at -4.5% YoY revenue growth and N/A YoY earnings growth on $1.96B TTM revenue (23.4% gross margin, -0.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FDMT cumulative revenue shifted +800.0% while SRPT shifted +520.0%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus 23.8% of Rev ($466M) (0 disclosures) for SRPT.
SRPT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas SRPT trades at 10.8x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (8.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus SRPT (-8.1% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, SRPT carries 54.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.